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Abstract
Background: Soft tissue sarcomas (STS) account for less than 1% of all malignancies. Approximately 50% of the
patients develop metastases with limited survival in the course of their disease. For those patients, palliative
treatment aiming at symptom relief and improvement of quality of life is most important. However, data on
symptom burden and palliative intervention are limited in STS patients.
Aim: Our study evaluates the effectiveness of a palliative care intervention on symptom relief and quality of life in
STS patients.
Design/setting: We retrospectively analysed 53 inpatient visits of 34 patients with advanced STS, admitted to our
palliative care unit between 2012 and 2018.
Symptom burden was measured with a standardised base assessment questionnaire at admission and discharge.
Results: Median disease duration before admission was 24 months, 85% of patients had metastases. The
predominant indication for admission was pain, weakness and fatigue. Palliative care intervention led to a
significant reduction of pain: median NRS for acute pain was reduced from 3 to 1 (p < 0.001), pain within the last
24 h from 5 to 2 (p < 0.001) and of the median MIDOS symptom score: 18 to 13 (p < 0.001). Also, the median stress
level, according to the distress thermometer, was reduced significantly: 7.5 to 5 (p = 0.027).
Conclusions: Our data underline that specialised palliative care intervention leads to significant symptom relief in
patients with advanced STS. Further efforts should aim for an early integration of palliative care in these patients
focusing primarily on the identification of subjects at high risk for severe symptomatic disease.
Keywords: Palliative care, Soft tissue sarcoma, MIDOS symptom score, Symptom burden, Early palliative care
intervention, Pain, Inpatient palliative care
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Key statements
What is already known about the topic?
– In a variety of advanced cancer diseases integration
of palliative care has a significant impact on patient
outcome, quality of care, length of hospital stay and
hospital costs and leads to a less aggressive
therapeutic approach during end-of-life care as well
as to more contentment in patients and their
relatives
– The early integration of palliative care leads to an
overall survival (OS) benefit
– Only limited data are available on the specific
challenges of palliative care interventions in the
context of soft tissue sarcoma (STS) and there are
no published data concerning an early integration of
palliative care in patients with sarcoma
What this paper adds
– This is the first report in STS patients analysing
hospital-based palliative care intervention, which
does not focus on end-of-life care, but on palliative
care intervention throughout the entire course of
the disease
– The interventions resulted in a significant reduction
of pain, an improvement of symptom burden and a
decreased stress level
Implications for practice, theory or policy
– Our analysis demonstrates that specialised palliative
care intervention leads to a significant symptom
relief throughout the entire course of the disease
– Further exploration of the effects of early integration
of palliative care on symptom relief, quality of life
and the possible improvement of overall survival in
STS patients is warranted
Background
Soft tissue sarcomas (STS) are rare and account for less
than 1% of malignancies [1, 2]. Originating from mesen-
chymal tissue, they represent a heterogeneous group
with more than 100 different histopathologically defined
tumours.
Comprising all disease stages, the 5-year overall sur-
vival is 50 to 60%. Nevertheless, metastases occur in up
to 50% of cases resulting in a poor outcome with overall
5-year survival of ~ 15%, only [3]. For patients with ad-
vanced disease, chemotherapy is the standard of care to
prolong survival and improve the quality of life. In this
setting, the median overall survival (OS) is 12.8 to 14.3
months, progression-free survival (PFS) is 4.6 to 7.4
months for doxorubicin monotherapy and doxorubicin
combination therapy, respectively [4]. These data dem-
onstrate a high unmet need for modern, effective therap-
ies for this group of patients and highlight the
importance of adequate palliative care strategies. Pub-
lished data on the symptom prevalence and severity in
advanced STS remain limited. Nevertheless, they suffi-
ciently describe the high symptom burden and demon-
strate the need for specialised diagnostics and optimised
care [5–7]. Additionally, since OS remains reduced, the
importance of palliative care needs to be increasingly
spotlighted.
The WHO defines palliative care as follows: “an ap-
proach that improves the quality of life of patients and
their families facing the problems associated with life-
threatening illness, through the prevention and relief of
suffering by means of early identification and impeccable
assessment and treatment of pain and other problems,
physical, psychosocial and spiritual “ [8]. Palliative care
is also defined as „applicable early in the course of ill-
ness, in conjunction with other therapies that are
intended to prolong life “ [8], and a relevant number of
analyses have addressed the benefit of early integration
of palliative care into cancer care [9]. According to Jack
et al., cancer patients in general benefit from a hospital-
based palliative care intervention regarding symptom re-
lief, with the largest effects on pain and anorexia [10].
Data about palliative care intervention in the context of
STS are sparse, and most authors concentrate on the de-
scription of symptom burden rather than assessing the
symptom relief achieved through palliative care interven-
tion. For example, Kawashima et al. reported that 93 and
78% of STS patients suffer from pain and nausea, re-
spectively, and that a total of 98% of STS patients re-
quires opioids within the last 2 weeks of life [11].
Our study aimed to assess the patterns of symptoms in
STS patients (np = 34) who have been treated in a hospital-
based palliative setting (ni = 53 interventions), and we fur-
ther intended to measure the benefit and effectiveness of a
hospital-based palliative care intervention regarding symp-
tom relief and quality of life in these patients.
In the context of STS, an optimal assessment for qual-
ity of life is not yet defined. During the last years, several
tools, e.g. standardised questionnaires, electronic patient
self-reporting and assessment by medical professionals,
have been evaluated. For example, Gough et al. used
questionnaires as well as semi-structured interviews in a
mixed methods longitudinal study in patients with ad-
vanced STS [12]. In the analysis published by Schuler
et al., patient-reported outcomes (PROs) were utilised to
evaluate overall quality of life (QoL) in patients undergo-
ing a palliative chemotherapy [13]. Hentschel et al. per-
formed multiple standardised assessments for QoL in
patients receiving systemic therapy and the value of add-
itional expert-consented supportive treatment recom-
mendations [14].
To our knowledge, there are only sparse data analysing
hospital-based palliative care in STS patients primarily
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focusing on early interventions throughout the entire
course of the disease, instead of end-of-life care.
Methods
We conducted a retrospective analysis of patients with
symptomatic advanced STS who were admitted to our
palliative care unit at the Charité between 2012 and
2018. The analysis was performed after patients’ consent
and according to the local ethical guidelines. Prerequisite
for inclusion in the analysis was the availability of data
both for admission and discharge.
This analysis included ni = 53 interventions of np = 34
STS patients who presented with different STS subtypes
(leiomyosarcoma as the most frequent subtype). Add-
itionally, we gathered information on disease duration
and prior therapies. Please see Table 1 for detailed pa-
tients’ characteristics.
The palliative care unit at Charité Virchow-Klinikum
belongs to the oncologic department and consists of an
inpatient ward with ten single bed rooms. The patients
are treated by a multidisciplinary team, including specia-
lised palliative care physicians, palliative care nurses,
physiotherapists, psychologists, dietists, musical thera-
pists and social service. Patients are either admitted from
home or transferred from other departments within the
Charité/ external clinics. Patients known to our onco-
logic department, which was the case for all sarcoma pa-
tients, can be admitted/transferred without prior
assessment of our palliative consulting service. For all
other patients, the palliative consulting service supervises
the indication for an admission to the palliative care
unit. If no admission is realised, the team simply coun-
sels and evaluates the needs of patients with palliative
malignancies/ chronic diseases. The aim for all patients
is an early integration of our palliative consulting service
to accompany these patients throughout the course of
their disease. For patients admitted to our ward, an indi-
vidualised therapeutic plan based on the patient’s symp-
tom burden is set up after the primary assessment,
thoroughly documented and individually adjusted daily
according to the standards of specialised inpatient pallia-
tive care intervention defined by the German Associ-
ation for Palliative Medicine [15]. The therapeutic
interdisciplinary interventional approach is a combin-
ation of pharmacological pain and symptom relief, con-
versational psychotherapy, music therapy, physiotherapy
and support of family care takers by social service. This
specialised inpatient palliative care intervention was of-
fered to all of the sarcoma patients.
Symptom burden was measured with a standardised
palliative base assessment questionnaire on admission
and at discharge. It consisted of an evaluation of the
Eastern Cooperative Oncology Group performance sta-
tus (ECOG), ranking from 0 to 5, which was first
published by Oken et al. in 1982 [16], pain (numeric rating
scale, NRS), a German version of the National Compre-
hensive Cancer Network (NCCN) distress thermometer (a
self-reported tool for cancer patients to screen for symp-
toms of distress using a scale from 0 to 10) [17], MIDOS
(minimal documentation system, the German version of
the Edmonton Symptom Assessment Scale) and personal
situational challenges. MIDOS corresponds to a self-
assessment of patients in palliative care indicating e.g. the
Table 1 Patients’ characteristics




Age at admission (years)
mean (range) 59 (21–80)





Pleomorphic sarcoma 3 (9)
Synovial sarcoma 3 (9)
Others 12 (35)
Tumour stage at diagnosis n (%)
curative 14 (41)
locally adcanced 7 (21)
metastasized 13 (38)
Tumour stage on admission n (%)
locally advanced 5 (15)
metastasized 29 (85)
Disease duration until admission (months)
mean (range) 24 (1–125)
Patients with initial surgery n (%)
yes 25 (74)
no 9 (26)
Patients with previous treatment lines n (%)
0 2 (6)
≥ 1 32 (94)
Patients with previous radiation n (%)
yes 25 (74)
no 9 (26)
Palliative care interventions n (%)
1 22 (67)
2 4 (12)
3 or more 7 (21)
n number, MPNST malignant peripheral nerve sheath tumor
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intensity of drowsiness, nausea, constipation, dyspnea,
weakness, fatigue, anxiety, lymphedema and well-being on
different scales. MIDOS ranges from 0 to 3, MIDOS 0
representing the absence of the symptom, MIDOS 3 indi-
cating a severe manifestation. It was developed to facilitate
and to standardise the evaluation of symptom clusters of
cancer patients. Validation of the MIDOS was first pub-
lished in 2000 by Radbruch et al. [18]. The MIDOS symp-
tom score summarises the symptom burden and consists
of a summation of each MIDOS score for all symptoms
(no symptom= 0 points/MIDOS 0, severe symptom= 3
points/MIDOS 3; maximum 48 for 16 symptoms in total).
Additional information on pain medication was col-
lected from patient records.
Data analysis was performed using IBM SPSS Statistics
25 (IBM Corp., Armonk, N.Y., USA) and Microsoft
Excel 14.4.7. The following nonparametric tests were
used: Wilcoxon signed ranks test for metric parameters
as well as McNemar test for dichotomic parameters. All
p values were two-sided, and p < 0.05 was considered
statistically significant. Concerning the duration of hos-
pitalisation, generalized estimating equation (GEE) was
combined with paired t tests and Sidak correction.
Results
Patient cohort and interventions
In our retrospective analysis 53 palliative care interven-
tions in 34 STS patients were analysed. Thirty-three per-
cent of the patients (np = 11) received more than one
palliative care intervention (21%, np = 7 more than
three). In our cohort, the median disease duration before
admission to the palliative care unit was 24months
(range 1–125 months).
85% of patients (np = 29) had metastases at admission,
15% had locally advanced disease (np = 5). In contrast,
only 59% of patients (np = 20) were in a palliative treat-
ment situation at the time of diagnosis (metastasised or
locally advanced). The majority of patients (94%, np =
32) had already received one or more regimen of chemo-
therapy, and 74% of patients (np = 25) had received radi-
ation before their first intervention. The same number
of patients (74%) had received surgery. The median pa-
tients’ age was 59 years (y) (range 21-80y). Please see
Table 1 for detailed patients’ characteristics.
The majority of admissions was from home (70%, ni =
37). The mean duration of hospitalisation was 15 days
(d) (range 2-36d). Analysing the different subgroups
(one, two and three or more interventions) there was a
significant difference concerning the duration of hospi-
talisation between the first (mean 17d) and the second
intervention (mean 11d, p = 0.007) as well as between
the second and the third intervention (mean 18d, p =
0.047). Patients who died on the ward had comparable
durations of inpatient interventions (13d, range 2–32).
Since parts of the palliative base assessment question-
naires were filled out by the patients themselves, on ad-
mission only 47% (ni = 25) were filled out completely
(excluding BMI), 45% (ni = 24) were incomplete, and 8%
(ni = 4) were not filled out. These numbers decreased
further at discharge: nearly the same number of ques-
tionnaires were filled out completely (45%, ni = 18), but
only 30% (ni = 12) were filled out partly, and 25% (ni =
10) were not filled out at all. Comparing the numbers on
admission, patients who died on the ward only com-
pleted the form in 15% (ni = 2) of cases (77% (ni = 10)
incomplete, 8% (ni = 1) not filled out). The most fre-
quent missing feature was the distress thermometer.
Therefore, for subsequent analysis, only a reduced num-
ber of interventions was included, respectively: pain ni =
53, ECOG ni = 34, MIDOS ni = 28, BMI ni = 5, distress
ni = 13.
Palliative care intervention
The predominant indication for admission to the pallia-
tive care unit was pain (ni = 23, 67% of patients),
followed by weakness (ni = 15, 28%) and symptomatic
tumor progression (ni = 15, 28%).
Pain management
Regarding pain medication, 68% (ni = 36) of patients
were already treated with opioid medication before ad-
mission, the majority of them at a high WHO cancer
pain ladder level (9% (ni = 5) WHO level II, 59% (ni =
31) WHO level III). 23% (ni = 12) of patients were ad-
mitted without any pain medication. Palliative care inter-
vention led to a significant reduction of pain: median
NRS for acute pain was reduced from 3 to 1 (p < 0.001),
while the pain experienced within the last 24 h before
admission and at discharge was reduced from 5 to 2
(p < 0.001, see Fig. 1). 32% (ni = 17) of patients received
an intensification of medication according to the WHO
cancer pain ladder. In contrast, patients who already re-
ceived potent opioids (WHO III) stood to benefit from
an opioid rotation (35%, ni = 11/31) and/or a change in
the route of administration (39%, ni = 12), e.g. transder-
mal to intravenous. Notably, in 28% (ni = 15) pain medi-
cation was not changed (see Table 2). Patients who died
throughout hospitalisation had higher pain levels on ad-
mission (median NRS acute pain: 4, median 24 h: 6).
Due to the clinical deterioration throughout the hospital
stay in these patients, no reliable data could be docu-
mented on the development of individual pain
perception.
Performance status
Interestingly, the median ECOG did not change
throughout the palliative care intervention (median of 3
on admission and at discharge).
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Stress level
The median psychosocial stress level, according to the
distress thermometer, was significantly reduced from 7.5
to 5 (p = 0.027) (see Fig. 2).
Symptom burden
Median MIDOS symptom score was reduced from 18 to
13 throughout the specialised palliative care intervention
(p < 0.001, see Fig. 3). Regarding the predominant severe
symptoms (MIDOS 3) weakness and fatigue, patients
benefited from the palliative care intervention. In par-
ticular, this consisted of specific spatial conditions, e.g.
single-bed-room, shared kitchen, terrace, and the multi-
professional team approach at the palliative care unit.
The available supportive programs included psychoon-
cologic counselling (as support for the whole family) as
well as depending on the respective symptom music
therapy (e.g. for pain, distress), physiotherapy (e.g. for
lymphedema, fatigue) in addition to optimisation of gen-
eral care and medication (antiemetics, laxatives).
While 57% (ni = 16) reported weakness on admission,
the rate dropped to 29% (ni = 8) at discharge (p = 0.008).
In concordance, fatigue dropped from 43% (ni = 12) on
admission to 18% (ni = 5) at discharge (p = 0.004). Other
symptoms such as dyspnea, nausea and constipation
were only present in less than 20% (dyspnea: 18%, nau-
sea: 7%, constipation: 7%). For details on different symp-
toms please refer to Table 3.
Nutritional status
The BMI on admission and at discharge was docu-
mented for only 9% of visits (ni = 5). Except for one pa-
tient, there was a tendency towards an improvement of
anorexia in the remaining ni = 4 patients. This was
achieved by enteral and/or partly parenteral high caloric
nutrition as well as appetite-enhancing drugs.
Patient discharge management
After completing the specialised palliative care interven-
tion, the majority of our STS patients (58%, ni = 31)
could be discharged home, 11% of patients (ni = 6) were
transferred to a hospice and 6% (ni = 3) to other institu-
tions such as geriatric clinics for further physiotherapeu-
tic treatment. Twenty-five percent (ni = 13) of our
patients died at the palliative care unit due to their ad-
vanced disease. For 32% (ni = 10) of the discharged pa-
tients, a continuation of antineoplastic therapy (e.g.
chemotherapy or radiation) was planned, and 42% (ni =
13) of the discharged patients were provided with add-
itional supportive care by a specialised palliative home
care team.
Fig. 1 Pain relief. a Boxplot for the assessment of pain relief achieved by inpatient palliative treatment; NRS = numeric rating scale, *p < 0.001. b
Individual pain relief
Table 2 Drug usage for pain relief
Total (n = 53) %
Medication on admission
WHO 0 12 23
WHO I 5 9
WHO II 5 9
WHO III 31 59
Medication at discharge
No change 15 28
Step up 17 32
Opioid rotation 11 21
Change in administration 14 26
reduction 4 8
WHO III on admission
opioid rotation at discharge 11 of 31 35
Change in administration at discharge 12 of 31 39
n number
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Discussion
Main findings/results of the study
This study of 34 STS patients admitted for specialised
palliative care intervention clearly demonstrates the ef-
fectiveness of these interventions documented by a stan-
dardised palliative base assessment. In detail, our
patients experienced a significant reduction of pain, an
improvement of symptom burden measured by the
MIDOS symptom score and a decreased stress level.
Therefore, our analysis demonstrates that specialised
palliative care intervention leads to significant symptom
relief and is useful for patients with advanced STS.
The importance and effectiveness of palliative care in-
terventions have been shown for multiple oncologic dis-
eases and are increasingly accepted [19–21]. Notably,
the early integration of palliative care leads to an OS
benefit which was first shown by Temel et al. in ad-
vanced lung cancer [22, 23]. In a variety of advanced
cancer diseases integration of palliative care has a signifi-
cant impact on patient outcome, quality of care, length
of hospital stay and hospital costs [20]. Additionally, the
involvement of a specialised palliative care team reduces
acute care hospital treatments [24] and leads to a less
aggressive therapeutic approach during end-of-life care
as well as to higher levels of satisfaction among patients
and their relatives [23]. Consequently, the early inclusion
of palliative care within the first 8 weeks after the diag-
nosis of advanced cancer disease is now part of national
and international clinical practice guidelines [25, 26].
Palliative care in an outpatient setting focusses on cop-
ing and support, symptom control, decision-making and
future planning [27]. In general, reasons for admittance
to an inpatient palliative care unit are symptom manage-
ment, support for distressed families, or care for the im-
minently dying patient [20]. There are little data directly
comparing community- and hospital-based palliative
Fig. 2 Stress level. a Assessment of stress level on admission/discharge measured by distress thermometer; *p = 0.027. b Distress thermometer
(adapted from www.netzwerk-palliativmedizin-essen.de)
Fig. 3 MIDOS symptom burden. a MIDOS symptom score on admission vs. at discharge; MIDOS = Minimal documentation system, *p < 0.001. b
Individual change of symptom burden (admission vs. discharge). The quantity of severe symptoms (MIDOS 3) decreases from admission to discharge,
whereas mild symptoms increase which results in a reduction of the total symptom burden
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care. Generally, patients requiring a hospital stay often
have a higher symptom burden, or a faster disease pro-
gression limiting the necessary transitions in their
homes. In the inpatient setting, a decrease of symptom
burden can often be enabled faster. For instance, an op-
timisation of the opioid medication requires frequent
clinical feedback, which cannot always be realised in the
outpatient setting.
So far, only limited data are available on the specific
challenges of palliative care interventions in the context
of STS. Similarities can be found comparing our patients
to other well-defined cohorts with different oncologic
diseases receiving specialised palliative care intervention,
especially when being integrated early into the thera-
peutic schedule [9, 23, 24, 28]. Patients with advanced
STS are known to require multidisciplinary approaches
due to the aggressiveness of the heterogeneous diseases
and the high occurrence of a severe symptom burden
[6]. Additionally, treatment of advanced and metasta-
sised STS often includes repeated surgical interventions,
which may be associated with complications and/or mu-
tilating procedures. Furthermore, the majority of thera-
peutic approaches in advanced or metastatic STS
comprises of chemotherapy and/or radiotherapy, pos-
sibly resulting in diverse side effects. STS often occurs at
a younger age, leading to explicitly challenging thera-
peutic demands. Especially in younger patients, mainten-
ance and/or recovery of abilities regarding activities of
daily living (ADL) is very important. Pain, weakness and
fatigue have been the predominant indications for ad-
mission in our cohort. Nevertheless, the median NRS for
acute pain at admission was not very high (median 3). In
our experience, patients with chronic pain often under-
estimate their actual pain level referring to the NRS. Ac-
cordingly, the mental burden of pain may not directly
correlate with the respective pain level. Presumably, the
majority of patients would retrospectively estimate their
acute pain level on admission higher than they did in
the situation of admission itself. Thus, the documented
pain level within the previous 24 h was significantly
higher in most cases (median 5).
Our data compare well to Gough et al. on patients
with advanced STS, who have documented pain, fatigue
and sleep disturbances as the most frequent symptoms
[6]. To our knowledge, there are no published data con-
cerning an early integration of palliative care in patients
with sarcoma. Even though we aim to integrate palliative
care early in the course of disease of our patients, some
patients were admitted late (median disease duration
until first admission 24months, maximum 125months),
had aggressive disease or unfortunately died throughout
the repeated palliative care interventions. These circum-
stances can partially explain why 25% of patients died
before they were discharged. Another reason for this
high percentage might be a less aggressive anti-tumour
therapeutic approach in those patients.
Published literature covering an end-of-life setting de-
scribes symptoms like dyspnea and fever more predom-
inantly than in our study. Our analysis also does not
entirely compare to other early palliative care interven-
tions, which are most often realised in an outpatient
and/or community-based setting [9, 27, 29].
Strength and weaknesses/limitations of the study
Our study is limited by the sample size of 34 patients
and the known restrictions of single-centre evaluation.
Furthermore, for many of theinterventions data was in-
complete. This was in part due to theself-assessment of
some outcomes by the patients, a high symptom burden
and a sometimes occuring communication barrier. Infor-
mation about e.g. the pain level, which is simple to as-
sess with the NRS, was available for all interventions. In
contrast, information about more complex questions
such as MIDOS and the distress thermometer was less
often complete. Additionally, there were obviously no
follow-up data about the deceased patients at discharge.
To evaluate the benefit of the intervention for these pa-
tients, follow-up assessments could have been done earl-
ier during the stay.
Besides the cohort size of our study, the heterogeneity
of sarcomas as well as the retrospective character of our
analysis make universal conclusions difficult, and in ac-
cordance our data should be validated prospectively and
in a larger patient cohort.




Weakness 16 (57%) 8 (29%)
Fatigue 12 (43%) 5 (18%)
Dyspnea 5 (18%) 1 (4%)
Insomnia 5 (18%) 1 (4%)
Fear 5 (18%) 2 (7%)
Loss of appetite 5 (18%) 3 (11%)
Family distress 5 (18%) 2 (7%)
Need for assistance in ADL 4 (14%) 6 (21%)
Lymphedema 4 (14%) 0 (0%)
Supply problems 3 (11%) 2 (7%)
Wound lesions 3 (11%) 0 (0%)
Nausea 2 (7%) 0 (0%)
Constipation 2 (7%) 2 (7%)
Depression 2 (7%) 0 (0%)
n number, ADL activities of daily living
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However, even though the optimal assessment for
QoL in patients with STS is not yet defined, and despite
our small patient population, we could show clinically
relevant effects and we still consider our data as pro-
foundly useful as published information on these pa-
tients remains sparse. Our study emphasises the
importance of palliative care intervention in advanced
oncologic disease, specifically in STS patients, and even
gives further evidence to support the earlier integration
of palliative care intervention in STS patients. Therefore,
we recommend an early integration of palliative care
measurement in the first 8 weeks, according to ASCO
clinical practice guidelines [25].
Some of our patients showed pain relief optimised
without any change in medication. Besides the amelior-
ation achieved by causal treatment of the pain source,
other essential factors are influencing the pain level. For
instance, an intensified individual support structure in-
cluding psychooncologic counselling, music therapy and
a reduction of psychosocial stress level, in general, may
also influence the pain intensity in the individual patient.
BMI was only evaluable in a tiny subset of patients
(ni = 5,9%). In general, the administration of parenteral
nutrition might be considered in patients with a survival
of more than some weeks, only [26]. Despite the small
sample size, in ni = 4 (8%) patients, we found a discrete
gain of body weight by optimisation of antiemetic treat-
ment and/or appetite increase as well as the provision of
high caloric nutrition if indicated.
What this study adds
To our knowledge, this is the first report in STS patients
analysing hospital-based palliative care intervention,
which does not focus on end-of-life care, but on pallia-
tive care intervention throughout the entire course of
the disease.
Conclusion
Our data show the impact of specialised palliative care
interventions with a multiprofessional approach on
symptom relief and quality of life in patients with ad-
vanced STS. Further exploration of the effects of early
integration of palliative care on symptom relief, quality
of life and the possible improvement of overall survival
in STS patients is warranted. Analyses in larger cohorts
are warranted to answer these questions.
For this purpose, patients with suspected STS should
be transferred to a specialised centre led by an interdis-
ciplinary team to complete histologic workup and initi-
ate causal therapy. This could simultaneously enable an
early standardised screening for physical and psycho-
social symptoms. With repeated assessments during the
course of their disease, subgroups with special need for
intensified support could be identified.
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